These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32851498)

  • 1. Understanding Fatigue in Primary Biliary Cholangitis.
    Phaw NA; Dyson JK; Mells G; Jones D
    Dig Dis Sci; 2021 Jul; 66(7):2380-2386. PubMed ID: 32851498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.
    Jones DE; Bhala N; Burt J; Goldblatt J; Prince M; Newton JL
    Gut; 2006 Apr; 55(4):536-41. PubMed ID: 16299032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC).
    Kaps L; Grambihler A; Yemane B; Nagel M; Labenz C; Ploch P; Michel M; Galle PR; Wörns MA; Schattenberg JM
    Dig Dis Sci; 2020 Oct; 65(10):3006-3013. PubMed ID: 31853781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional capacity is significantly impaired in primary biliary cirrhosis and is related to orthostatic symptoms.
    Newton JL; Elliott C; Frith J; Ghazala C; Pairman J; Jones DE
    Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):566-72. PubMed ID: 21593676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.
    Dyson JK; Wilkinson N; Jopson L; Mells G; Bathgate A; Heneghan MA; Neuberger J; Hirschfield GM; Ducker SJ; ; Sandford R; Alexander G; Stocken D; Jones DE
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1039-1050. PubMed ID: 27640331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic fatigue should not be overlooked in primary biliary cholangitis.
    Shahini E; Ahmed F
    J Hepatol; 2021 Sep; 75(3):744-745. PubMed ID: 33640400
    [No Abstract]   [Full Text] [Related]  

  • 8. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
    Sy AM; Ferreira RD; John BV
    Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.
    Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A;
    Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for the treatment of primary biliary cholangitis.
    Phaw NA; Dyson JK; Jones D
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Liver Transplantation for Primary Biliary Cholangitis.
    Aguilar MT; Carey EJ
    Clin Liver Dis; 2018 Aug; 22(3):613-624. PubMed ID: 30259857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study.
    Zhu J; Shi Y; Zhou X; Li Z; Huang X; Han Z; Wang J; Wang R; Ding J; Wu K; Han Y; Fan D
    Front Med; 2013 Jun; 7(2):255-63. PubMed ID: 23179137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.